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n-3 PUFA may exert favourable effects on several processes that may inhibit the athero-
sclerotic process. However, the role of n-3 PUFA in lowering the risk of atherosclerotic
CVD (ASCVD) has been fiercely debated. In the present paper, we summarise the main
findings from previous follow-up studies of intake and studies using adipose tissue as an
objective biomarker to investigate exposure to n-3 PUFA in relation to ASCVD risk
and discuss some perspectives for further research. The majority of previous studies inves-
tigating intake of marine- and plant-based n-3 PUFA have focused on CHD while other
ASCVD such as ischaemic stroke and peripheral artery disease have been less studied.
However, recent data from Danish Diet, Cancer and Health cohort suggest that marine
n-3 PUFA may be inversely associated with risk of myocardial infarction, ischaemic stroke
and peripheral arterial disease caused by atherosclerosis. The effect of the plant-derived n-3
PUFA α-linolenic acid on ASCVD is less clear and several gaps in the literature remain to
be explored.
α-linolenic acid: EPA: DHA: Atherosclerotic cardiovascular disease
Atherosclerosis is the underlying disease process that
may result in atherosclerotic CVD (ASCVD) including
myocardial infarction, ischaemic stroke and peripheral
arterial disease (PAD).
n-3 PUFA are organic acids that contain more than
one double bond in the aliphatic chain(1). n-3 PUFA
can be divided into the short-chain n-3 PUFA, α-linolenic
acid (ALA, 18:3n-3) and the longer-chain (LC) n-3
PUFA EPA (20:5n-3), docosapentaenoic acid (DPA,
22:5n-3) and DHA (22:6n-3)(2).
ALA is found in high concentrations in walnuts and
plant oils based on rapeseed, soyabean and flaxseed,
but can also be acquired from other sources such as
green leafy vegetables, whole-grain cereals, margarines,
dairy products and meat(3–5). The primary source of
EPA and DHA is seafood especially oily fish such as sal-
mon, anchovies, herring, mackerel, tuna and sardines(6).
ALA is the most abundant n-3 PUFA in the diets of sub-
jects who do not consume very high amounts of oily fish
or concentrated supplements of EPA and/or DHA(7).
The typical intake of n-3 PUFA in adults varies substan-
tially by country, but most Western populations consume
approximately 0·5 to 2·3 g/d ALA(7) and 0·1 to 0·6 g/d
EPA+DHA. ALA can be converted into EPA and
DHA by a series of desaturation, elongation and
β-oxidation reactions(8). The conversion efficiency of
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ALA into EPA and DHA appears to be limited in
human subjects with reported conversion percentages
of ALA to EPA <10 % and to DHA <1 %(7,9).
However, the conversion efficiency appears to be better
in women and especially in those of reproductive
age(10). Also, interplay between fatty acids and genetics
are believed to influence the metabolism of ALA(11).
ALA has been ascribed anti-inflammatory, anti-
atherosclerotic and anti-thrombotic effects(12), but con-
troversy remains whether these suggested mechanisms
of action can be attributed to the effects of ALA per
se or its role as a precursor for LC n-3 PUFA and
beyond. Accumulating evidence suggests that EPA
and DHA may exert favourable effects on several bio-
logical processes that may influence atherosclerosis
development including beneficial effects on inflamma-
tion, blood pressure, TAG, platelet reactivity, endothe-
lial function and stabilisation of atherosclerotic
plaques(1,13).
Dietary studies assessing consumption of n-3 PUFA
using self-reported questionnaires are prone to measure-
ment error, which may result in an attenuation of
observed associations and loss of statistical power. In
contrast, the content of n-3 PUFA in human tissue
may reflect an objective measure of intake and metabol-
ism and the endogenous exposure of n-3 PUFA(11,14),
which may be more important from a biological point
of view. Shorter-term biomarkers may include the con-
tent of n-3 PUFA in serum, plasma or erythrocytes
reflecting the exposure from days to months, whereas
the content in adipose tissue is believed to represent the
long-term exposure during the previous 1–2 years(11,14).
Thus, adipose tissue content of n-3 PUFA is considered
the gold standard biomarker to investigate the role of
n-3 PUFA in relation to chronic diseases such as
ASCVD(11).
Here, we will summarise the main findings from previ-
ous follow-up studies of intake and studies using adipose
tissue as an objective biomarker to investigate exposure
to n-3 PUFA in relation to ASCVD risk and discuss
some perspectives for further research.
α-Linolenic acid and atherosclerotic CVD
ALA has been proposed to be an important component
of the Mediterranean diet(15), which has been suggested
to lower the risk of major cardiovascular events(16).
Most previous studies investigating the association
between intake of ALA and ASCVD have focused on
CHD and to some extent also on ischaemic stroke.
α-Linolenic acid and CHD
Several follow-up studies have investigated the associ-
ation between ALA intake and the rate of total or fatal
CHD(4,5,17–27). Early findings from the mid-1980s based
on data from the Usual Care group of the Multiple
Risk Factor Intervention Trial (n 6250) suggested that
intake of ALA expressed as percentage of total kilocal-
ories was inversely associated with mortality from
CHD in analyses including 175 cases identified during
10·5 years of follow-up amongst US men(20). Also,
early findings from the US Health Professionals
Follow-up Study (n 43 757) indicated an inverse associ-
ation between ALA expressed as a percentage of total
energy intake and the rate of myocardial infarction
including 734 events amongst men followed for 6
years(21). However, the association was only statistically
significant in analyses including adjustment for trad-
itional risk factors and dietary risk factors and no statis-
tically significant association was found between an ALA
intake ranging between 0·9 g/d in the first quintile to 1·5
g/d in the fifth quintile in analyses of 229 cases of fatal
myocardial infarction(21). A Finnish study conducted
amongst 21 930 male smokers followed for a median of
6·1 years found no consistent association between
energy-adjusted ALA intake and the rate of total CHD
(1399 cases) or fatal CHD (635 cases)(22). However, indi-
cations of a lower rate of fatal CHD were observed in
analyses including additional adjustment for trans fatty
acids, MUFA and SFA when comparing an ALA intake
of median 2·5 g/d in the fifth quintile with an intake of
0·9 g/d in the first quintile (hazard ratio (HR) 0·75, 95
% CI 0·52, 1·10)(22). Also, an inverse association between
energy-adjusted ALA intake and the rate of fatal CHD
(2697 cases) was observed amongst men and women fol-
lowed for nearly 15 years in the Singapore Chinese
Health Study (n 60 298) when comparing an average
intake of 0·86 g/d in the fourth quartile with an intake
of 0·36 g/d in the first quartile (HR 0·82, 95 % CI 0·71,
0·93)(23). In an updated report from the Health
Professionals Follow-up Study including 14 years of
follow-up, Mozaffarian et al.(24) suggested that intake
of energy-adjusted ALA intake was associated with a
lower rate of CHD in subjects with intake of LC n-3
PUFA below 100 mg/d, whereas no consistent associ-
ation was observed amongst subjects with a higher intake
of LC n-3 PUFA. Initial analyses from the Nurses
Health Study (n 76 283) with 10 years of follow-up sug-
gested an inverse association between the
energy-adjusted intake of ALA and the rate of fatal
CHD (232 cases) in analyses including adjustment for
traditional CHD risk factors and dietary risk factors,
while no consistent pattern of association was observed
between ALA intake and the rate of non-fatal myocar-
dial infarction (597 cases)(4). The lowest rates of fatal
CHD were observed when comparing an ALA intake of
1·36 g/d in the fifth quintile with an intake of 0·71 g/d
in the first quintile (HR 0·55, 95 % CI 0·32, 0·94)(4).
However, in an updated report from the Nurses’
Health Study of 18 years of follow-up, no consistent pat-
tern of association was observed between energy-
adjusted ALA intake and the rate of fatal CHD (641
cases) or non-fatal myocardial infarction (1604
cases)(25). Also, several other follow-up studies have not
confirmed an inverse association between ALA intake
and the rate of CHD or fatal CHD(17–19,26,27). A pooled
analysis of eight American and European cohorts inves-
tigated the association between energy-adjusted ALA
intake and the rate of CHD and fatal CHD amongst
148 675 women and 80 368 men(19). During 4–10 years






















Downloaded from https://www.cambridge.org/core. IP address: 130.225.247.95, on 27 Jul 2021 at 06:49:35, subject to the Cambridge Core terms of use, available at
of follow-up, 3337 total CHD and 1191 fatal CHD
events occurred amongst men, while 1156 total CHD
and 560 fatal CHD events occurred amongst
women(19). In analyses including adjustment for trad-
itional risk factors for CHD, energy-adjusted intake of
ALA was not associated with the rate of total or fatal
CHD in men or women(19). However, in analyses includ-
ing additional adjustment for dietary factors, indications
of lower rates of total CHD (HR 0·85, 95 % CI 0·72,
1·01) for each additional 1 g ALA consumed) and fatal
CHD (HR 0·77, 95 % CI 0·58, 1·01) were observed in
men, whereas no consistent associations were observed
in women(19). The median energy-adjusted ALA intake
was 1·01 g/d in women (80 % central range: 0·58; 1·64
g/d) and 1·17 g/d in men (80 % central range: 0·64;
1·62 g/d)(19). Data from the Diet, Cancer and Health
(DCH) cohort (n 53 901) suggested that energy-adjusted
ALA intake was not appreciably associated with the rate
of myocardial infarction in men (2124 cases) or women
(854 cases) during 17 years of follow-up in analyses
adjusted for established CHD risk factors(5). However,
an indication of a lower rate of myocardial infarction
was observed amongst men in analyses including add-
itional adjustment for dietary risk factors when compar-
ing the highest quintile of intake (≥2·54 g/d) with the
lowest (<1·67 g/d; HR 0·90, 95% CI 0·76, 1·07)(5). A
recent systematic review and meta-analysis suggested a
modest non-linear inverse association between ALA
intake and CHD with the lowest rates of CHD up to a
daily intake of ALA of 1·4 g/d and a dose-dependent
inverse association between ALA intake and the rate of
fatal CHD(28). In this meta-analysis, the authors gener-
ally included effect estimates derived from statistical
models including adjustment for CHD risk factors and
dietary factors when available(28).
Few studies have investigated adipose tissue content of
ALA in relation to risk of CHD(5,29–33). A case–control
study including both men and women from Costa Rica
reported a statistically significant inverse association
between adipose tissue content of ALA and the odds of
non-fatal myocardial infarction (1819 cases)(29). The low-
est odds for non-fatal myocardial infarction were
observed when comparing the adipose tissue content of
ALA in the ninth decile (median 0·88 %) with the lowest
decile (0·36 %) in analyses including CHD risk factors
and SFA, linoleic acid and trans fatty acids (OR: 0·37,
95 % CI 0·23, 0·59)(29). However, no significant difference
in the odds of non-fatal myocardial infarction was
observed between the seventh decile and tenth decile of
adipose tissue content of ALA (0·70 % to 1·04 %)(29).
Few other smaller case–control studies have explored
the associations between adipose tissue content of ALA
and myocardial infarction, but results have been incon-
sistent(30–33). In analyses including adjustment for estab-
lished CHD risk factors, a positive association between
adipose tissue content of ALA and myocardial infarction
was observed in men (1994 cases) and a weak U-shaped
association was observed in women (770 cases) amongst
subjects enrolled in the DCH cohort, but none of these
associations were statistically significant(5). In women,
the lowest rates of myocardial infarction was observed
around the median adipose tissue content of ALA
(0·82 %)(5).
α-Linolenic acid and ischaemic stroke
Few studies have investigated associations between intake
of ALA and the risk of ischaemic stroke(18,27,34–36). In
the MORGEN Study, lower rates of total ischaemic
stroke with energy-adjusted intake of ALA were reported
amongst men and women (n 19 896) including 144 cases
identified during a median of 10·5 years(27). When com-
paring with the lowest quintile, the HR in the second
to fifth quintile of ALA intake were 0·63 (95 % CI
0·39, 1·02); 0·45 (95 % CI 0·26, 0·77), 0·55 (95 % CI
0·33, 0·92) and 0·70 (95 % CI 0·43, 1·12), respectively(27).
The energy-adjusted ALA intake ranged between a
median of 1·0 g/d in the first quintile to 1·9 g/d in the
fifth quintile(27). In the Cardiovascular Health Study
(n 2583) a cohort of US men and women, a median
ALA intake of 2·44 % of total fatty acids in the fifth
quintile was associated with a non-significant lower rate
of total ischaemic stroke (HR 0·70, 95 % CI 0·47, 1·04)
compared with an intake of 1·33 % in the first quintile,
but no consistent pattern of association was observed
across quintiles in analyses of 278 cases identified during
12 years of follow-up(18). In addition, no consistent asso-
ciation was found between intake of ALA expressed as
percentage of total energy intake and the rate of total
ischaemic stroke in 807 cases identified during 22 years of
follow-up in the Women’s Health Study (n 38 392)(35).
Further, an energy-adjusted ALA intake ranging
between a mean of 0·9 g/d in the first quintile to 1·5 g/d
in the fifth quintile was not associated with the rate of
total ischaemic stroke amongst women in the Swedish
Mammography Cohort (n 34 670), which included 1310
cases identified during a median of 10·4 years of
follow-up(34). Neutral findings were also reported be-
tween the energy-adjusted intake of ALA and the rate
of total ischaemic stroke amongst men and women
enrolled in the DCH cohort (n 55 018) including 1859
cases identified during 13·5 years of follow-up(36). Also,
no consistent pattern of association was observed
between ALA intake and the rate of ischaemic stroke
subtypes including ischaemic stroke due to large artery
atherosclerosis, small-vessel occlusions or cardioembo-
lisms(36). The energy-adjusted ALA intake in the first
quintile was 1·10 g/d and 2·60 g/d in the fifth quintile.
There is limited knowledge on the association between
adipose tissue content of ALA and the rate of ischaemic
stroke. However, a recent case–cohort study based on
data from the DCH cohort reported a U-shaped pattern
of association between adipose tissue content of ALA
and the rate of total ischaemic stroke, but the association
was not statistically significant (P= 0·172) in analyses
including 1755 cases identified during 13·4 years of
follow-up(37). In analyses of ischaemic stroke subtypes,
a statistically significant U-shaped association was
observed between adipose tissue content of ALA and
the rate of ischaemic stroke due to large artery athero-
sclerosis (P = 0·017) with the lowest rates observed
around the median adipose tissue content of ALA
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(0·84 %)(37). When comparing with the lowest quintile,
the HR in the second to fifth quintile of adipose tissue
content of ALA and the rates of ischaemic stroke due
to large artery atherosclerosis were 0·72 (95 % CI 0·48,
1·08); 0·63 (95 % CI 0·41, 0·96); 0·83 (95 % CI 0·56,
1·22) and 0·95 (95 % CI 0·65, 1·40) respectively(37). In
contrast, no consistent association was found between
adipose tissue content of ALA and the rate of ischaemic
stroke due to small-vessel occlusion and a positive statis-
tically non-significant association was observed between
ALA and the rate of ischaemic stroke due to
cardioembolism(37).
α-Linolenic acid and peripheral arterial disease
To our knowledge, no previous follow-up studies have
explored the associations between intake and adipose tis-
sue content of ALA in relation to development of PAD.
Longer-chain n-3 fatty acids and atherosclerotic CVD
A large number of epidemiological studies has investi-
gated dietary intake of LC n-3 PUFA in relation to
risk of CVD with the vast majority of studies focusing
on CHD while ischaemic stroke and PAD have been
less studied.
Longer-chain n-3 PUFA and CHD
Since the late 1970s where Dyerberg and colleagues in a
seminal paper hypothesised that LC n-3 PUFA might
protect against atherosclerosis and thrombosis(38) this
has been the subject of multiple investigations. The pro-
tective effect of seafood against CHD reported in
Greenland Inuit was confirmed in several epidemio-
logical studies of other populations, which previously
has been reviewed in detail(6,39). In the following, we
will focus on studies using data from the DCH cohort,
which have investigated both dietary intake and adipose
tissue content of LC-n-3 PUFA in relation to risk of
CHD(40–43). The reported median intake of total LC
n-3 PUFA in this cohort was approximately 700 mg/d
with EPA and DHA constituting 180 mg/d and 430
mg/d, respectively(42). Early findings from the DCH
cohort (n 53 802) suggested indications of inverse asso-
ciations between intake of total LC n-3 PUFA, EPA,
DPA and DHA and the rate of acute coronary syndrome
in men, whereas no consistent pattern of associations
were found in women after adjustment for established
risk factors and potential dietary factors(40). Acute coron-
ary syndrome was defined as unstable angina pectoris
and non-fatal and fatal myocardial infarction and during
7·6 years of follow-up 852 male and 272 female cases
were identified(40). Also, indications of lower rates of
acute coronary syndrome were observed in analyses of
adipose tissue content of total LC n-3 PUFA, EPA,
DHA and DPA amongst men (779 cases) although
only statistically significant when comparing the fifth
quintile of total n-3 PUFA and DHA with the first quin-
tile, respectively(41). No consistent pattern of association
was observed amongst women (233 cases)(41). However, a
recent study based on the DCH cohort (n 54 904) includ-
ing 17 years of follow-up of investigating intake of LC
n-3 PUFA on myocardial infarction found indications
of lower rates of myocardial infarction amongst subjects
in the highest quintile of intake of total n-3 PUFA, EPA,
DPA and DHA compared with the lowest quintile in
both men (2136 cases) and women (892 cases) although
only modestly amongst men(42). In analyses of adipose
tissue content of LC n-3 PUFA, indications of inverse
associations were observed between EPA and myocardial
infarction and between DHA and myocardial infarction
(2814 cases)(43). In contrast, a high content of DPA in
adipose tissue was associated with a higher rate of myo-
cardial infarction(43). In analyses including adjustment
for traditional risk factors, HR of 0·76 (95 % CI 0·63,
0·91) and 0·78 (95 % CI 0·64, 0·95) were found for
EPA and DHA when comparing the highest and lowest
quintile, respectively(43).
Longer-chain n-3 PUFA and ischaemic stroke
Some studies have investigated intake of LC n-3 PUFA
in relation to risk of total ischaemic stroke(34,35,44–51).
Early findings from women enrolled in the Nurses’
Health Study (n 79 839) suggested indications of an
inverse association between energy-adjusted intake of
EPA+DHA and the rate of total ischaemic stroke in
303 cases identified during 14 years of follow-up(44).
The HR in the second to fifth quintile of EPA+DHA
intake were 0·83 (95 % CI 0·59, 1·18), 0·67 (95 % CI
0·47, 0·98), 0·82 (95 % CI: 0·57, 1·18) and 0·71 (95 %
CI 0·46, 1·10), respectively in analyses adjusted for car-
diovascular and dietary risk factors when compared
with the lowest quintile(44). The energy-adjusted intake
of EPA+DHA was 77 mg/d in the first quintile and
481 mg/d in the fifth quintile(44). Also, an inverse associ-
ation between energy-adjusted EPA+DHA intake
and the rate of total ischaemic stroke was observed
amongst men followed during 12 years in the Health
Professional Follow-up Study (n 43 671) although not
statistically significantly comparing the highest quintile
of intake with the lowest(45). The HR in the second to
fifth quintile of EPA+DHA intake were 0·56 (95 % CI
0·35, 0·88); 0·63 (95 % CI 0·40, 0·98); 0·54 (95 % CI
0·32, 0·91) and 0·73 (95 % CI 0·43, 1·25) in 377 cases
adjusted for cardiovascular and dietary risk factors
when compared with the lowest quintile, respectively(45).
The energy-adjusted intake of EPA+DHA was below
50 mg/d in the first quintile and above 600 mg/d in the
fifth quintile(45).
Lower rates of total ischaemic stroke were also found
across quintiles of energy-adjusted EPA+DHA intake in
women followed for 10·4 years in the Swedish
Mammography Cohort (n 34 670)(34). The HR in the
second to fifth quintile of EPA+DHA intake were
0·88 (95 % CI 0·74, 1·04); 0·84 (95 % CI 0·70, 1·01);
0·83 (95 % CI 0·69, 0·99) and 0·83 (95 % CI 0·69, 0·99)
in analyses of 1310 cases adjusted for cardiovascular
risk factors and dietary risk factors when compared
with the lowest quintile, respectively(34). The intake of
EPA+DHA ranged between a median of 131 mg in
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the first quintile and 559 mg in the fifth quintile(34). In the
MORGEN study, lower rates of total ischaemic stroke
with intake of energy-adjusted EPA+DHA in analyses
including adjustment for cardiovascular and dietary
risk factors were observed in both men (80 cases) and
women (64 cases), but the CI were wide and not statistic-
ally significant(47). The median intake of EPA+DHA in
this Dutch population ranged between 36 mg in the first
quintile to 225 mg in the fifth quintile in women and
between 44 mg and 241 mg in the fifth quintile in
men(47). In contrast, five other follow-up studies did not
find consistent associations between intake of EPA+
DHA and the rate of total ischaemic stroke(35,46,48,50,51).
A recent study based on data from the DCH cohort
investigated the association between dietary intake and
adipose tissue content of LC n-3 PUFA and the risk of
total ischaemic stroke and ischaemic stroke subtypes dur-
ing 13·5 years of follow-up(49). In analyses of dietary
intake, no consistent associations were found between
intake of total n-3 PUFA, EPA or DHA and the rate
of total ischaemic stroke while DPA was associated
with a higher rate of total ischaemic stroke in 1879
cases when comparing the highest quartile of intake
with the lowest(49). However, in analyses of ischaemic
stroke subtypes lower rates of ischaemic stroke due to
large artery atherosclerosis were associated with a high
intake of total LC n-3 PUFA (HR 0·69, 95 % CI 0·50,
0·95), EPA (HR: 0·66, 95 % CI: 0·48, 0·91) and DHA
(HR 0·72, 95 % CI 0·53, 0·99) in analyses including 319
cases(49). In contrast, indications of higher rates of ischae-
mic stroke due to cardioembolisms were observed with
intake of LC n-3 PUFA, while no consistent associations
were observed between LC n-3 PUFA and ischaemic
stroke due to small-vessel occlusions(49). No association
was observed between the content of total LC n-3
PUFA in adipose tissue and the rate of total ischaemic
stroke in 1755 cases(49). However, the content of EPA
in adipose tissue was inversely associated with the rate
of total ischaemic stroke when comparing the highest
with the lowest quartile (HR 0·74 (95 % CI 0·62,
0·88)(49). In contrast, the content of DPA in adipose tis-
sue seemed to be associated with a higher rate of total
ischaemic stroke, while no association was found for
DHA(49). Thus, the associations between LC n-3 PUFA
seemed to differ amongst subtypes of ischaemic stroke.
Interestingly, the content of EPA in adipose tissue was
inversely associated with the rate of ischaemic stroke
due to large artery atherosclerosis in analyses of 300
cases with a HR of 0·52 (95 % CI 0·36, 0·76) when com-
paring the highest with the lowest quartile of EPA in adi-
pose tissue(49). Thus, the content of EPA in adipose tissue
was inversely associated with a lower rate of ischaemic
stroke due to small-vessel occlusion in analyses in 781
cases with a HR of 0·69 (95 % CI 0·55, 0·88) while a
higher rate of ischaemic stroke due to cardioembolism
was observed in subjects with a high content of EPA in
adipose tissue(49). The content of DPA and DHA in adi-
pose tissue was associated with higher rates of ischaemic
strokes due to cardioembolism while no consistent asso-
ciation was found for ischaemic strokes due to large
artery atherosclerosis or small-vessel occlusions(49). The
observation that both intake and adipose tissue content
of EPA in particular may be associated with a lower
rate of ischaemic stroke due to large artery atheroscler-
osis is of interest because this subtype of ischaemic stroke
is believed to be caused mainly by atherosclerosis.
Longer-chain n-3 PUFA and peripheral arterial disease
To our knowledge, no previous large follow-up studies
have investigated the association between the intake of
LC n-3 PUFA and the risk of PAD. However, a recent
case–cohort study based on data from the DCH cohort
including 870 incident PAD cases suggested that a high
content of EPA+DHA and in particular of EPA in
adipose tissue was associated with a lower rate of PAD
during 13·5 years of follow-up(52). The content of EPA
in adipose tissue was associated with a dose-dependent
lower rate of PAD with a HR of 0·55 (95 % CI 0·41,
0·74) when comparing the highest quintile of EPA with
the lowest(52). The association between DHA indicated
a lower rate of PAD above the median content in adipose
tissue with a HR of 0·79 (95 % CI 0·59, 1·06) when com-
paring the highest with the lowest quintile(52). In contrast,
the content of DPA in adipose tissue seemed to be
associated with a higher rate of PAD(52).
Conclusions
Follow-up studies indicate that intake of LC n-3 PUFA
derived mainly from seafood may be inversely associated
with the risk of myocardial infarction, ischaemic stroke
caused by atherosclerosis and PAD, whereas the role of
the mainly plant-derived n-3 PUFA ALA in ASCVD is
less clear with conflicting results reported. The use of adi-
pose tissue as a gold standard long-term objective bio-
marker to reflect intake and metabolism has supported
the view that EPA, but maybe also DHA, may be asso-
ciated with a lower risk of atherosclerotic vascular dis-
ease. Recent results from the DCH cohort have
generally shown stronger associations for EPA than
DHA in adipose tissue on myocardial infarction, ischae-
mic stroke caused by atherosclerosis and PAD. However,
whether the observed difference is due to different bio-
logical effects related to atherosclerosis remains unclear
and further studies investigating the independent bio-
logical effects of EPA and DHA are warranted(53). The
use of complementary measures of exposure including
estimated intake and the content in adipose tissue or
other biomarkers of LC n-3 PUFA may each contribute
with valuable information despite their different limita-
tions. Estimation of dietary intake of n-3 PUFA are
prone to measurement error, which is inevitable due to
self-reported intakes of foods and calculation of nutrient
intakes based on food composition tables that may be
imprecise. In contrast, the content of n-3 PUFA in adi-
pose tissue may represent a more objective marker of
intake. The use of biomarkers may be of particular
importance to reflect exposure to ALA because import-
ant sources such as plant oils and margarines may be
used in food preparation or included in convenience
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foods and may therefore be difficult to recognise and
quantify in questionnaires(12). However, the content of
PUFA in adipose tissue may also be influenced by
metabolism(7). Endogenous conversion of ALA may con-
tribute to tissue levels of LC n-3 PUFA, predominantly
EPA, although the significance of this is not clear
because high intakes of linoleic acid relative to ALA in
most Western populations may favour conversion of
linoleic acid over ALA due to metabolism by shared
enzymes(7). Also, intake of LC n-3 PUFA may inhibit
the metabolism of ALA(7). Interestingly, most studies
reporting lower risk of atherosclerotic vascular disease
with intake of ALA has been conducted in populations
with a relatively low intake of LC n-3 PUFA and the pre-
vious findings by Mozaffarian et al.(24) support the view
that the association between ALA intake and ASCVD
may depend on intake of LC n-3 PUFA. Thus, the neu-
tral findings of the associations between ALA intake and
myocardial infarction, ischaemic stroke and PAD in the
DCH cohort might be due to the high intake of LC n-3
PUFA in this population(5,36,37). Also, competitive
mechanisms between ALA and the linoleic acid may
affect the association between ALA and ASCVD.
Several studies investigating intake of n-3 PUFA in
relation to ASCVD included adjustment for both cardio-
vascular risk factors and potential dietary risk factors in
the same statistical model. Analyses including adjust-
ment for dietary factors may contribute with insight in
the aetiology to exposure to n-3 PUFA by limiting poten-
tial residual confounding from diet. Previous studies that
have investigated associations between n-3 PUFA and
ASCVD in analyses including adjustment for both
cardiovascular risk factors and diet have used a variety
of different nutrients such as other PUFA, MUFA,
SFA, trans fatty acids, vitamins, fibre, β-carotene,
electrolytes or proteins while some did include adjust-
ment for foods such as fruit, vegetables or meat as
well. However, the interpretation of the observed mea-
sures of association may not be straightforward if major
restrictions are introduced to the underlying dietary pat-
tern by adding of dietary covariates and the public health
relevance may be reduced. Therefore, analyses including
traditional risk factors of the outcome of interest and
analyses including dietary risk factors in addition to
traditional risk factors using separate statistical models
represent two different approaches which each may
contribute with a more detailed interpretation of the
associations of interest.
Total ischaemic stroke is a heterogeneous condition
and the different associations observed between LC n-3
PUFA and ischaemic stroke subtypes in the DCH cohort
may suggest that in studies of aetiology separate analyses
of ischaemic stroke subtypes may contribute to a deeper
understanding of the underlying biology of exposure to
LC n-3 PUFA.
In summary, prospective studies using estimated
intakes or adipose tissue content of marine and the plant-
derived n-3 PUFA have contributed with important
knowledge on the role of these PUFA in relation to
development of ASCVD, but several gaps in the litera-
ture remains to be elucidated.
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